Feasibility of implementation of the early tumor shrinkage as a potential predictive marker to daily clinical practice in patients with RAS wild type metastatic colorectal cancer, treated with cetuximab - a non-interventional observational study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Early tumor shrinkage (ETS) is not feasible in routine Czech oncology care due to long radiographic control intervals. Most patients with metastatic colorectal cancer (mCRC) did not achieve significant tumor regression within the first 8 weeks of first-line therapy.
Area Of Science
- Oncology
- Clinical Practice Research
Background
- A prospective, real-world study assessed the feasibility of implementing the Early Tumor Shrinkage (ETS) concept in the Czech Republic.
- The study focused on daily clinical practice in oncology.
Purpose Of The Study
- To evaluate the time to first radiographic control (TFRC) in real-world settings.
- To determine the proportion of metastatic colorectal cancer (mCRC) patients achieving ≥ 20% tumor regression within 8 weeks of first-line therapy.
Main Methods
- Non-interventional, multicentric, single-arm, prospective study.
- Data collected on TFRC and tumor regression rates in patients receiving first-line therapy.
- Analysis of treatment response to cetuximab plus chemotherapy.
Main Results
- Median TFRC across centers exceeded 12 weeks (range 14.0-36.4 weeks).
- Only 3% of patients had TFRC ≤ 8 weeks; 1% achieved ≥ 20% tumor regression by day 60.
- Overall response rate (ORR) to first-line cetuximab + chemotherapy was 51% (42.4% unconfirmed partial response, 8.6% unconfirmed complete response).
Conclusions
- The standard time parameter for ETS is not realistically applicable in routine mCRC care in the Czech Republic.
- First-line cetuximab plus chemotherapy demonstrated a 51% ORR in mCRC patients.
- Higher response rates were observed in patients with left-sided primary tumors; cetuximab/FOLFOX may be more active than cetuximab/FOLFIRI in right-sided RAS wild-type mCRC.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.